Raghavan D, Koczwara B, Javle M
Division of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA.
Eur J Cancer. 1997 Apr;33(4):566-74. doi: 10.1016/s0959-8049(96)00510-2.
Despite the use of cytotoxic chemotherapy for advanced prostate cancer for half a century, its clinical utility in this setting remains undefined. Based on traditional methods of assessment, the list of the most active cytotoxic agents includes cyclophosphamide, doxorubicin, mitoxantrone and cisplatin. With the introduction of more structured methods of assessment, including careful assessment of indices of quality of life and serial measurement of serum prostate-specific antigen (PSA), the role of cytotoxic agents is being re-assessed. In view of the cell cycle characteristics of prostate cancer, there appears to be an emerging role for combination inhibitors of mitosis, including estramustine in combination with the vinca alkaloids, etoposide or paclitaxel.
尽管细胞毒性化疗用于晚期前列腺癌已有半个世纪，但它在这种情况下的临床效用仍不明确。基于传统的评估方法，最有效的细胞毒性药物包括环磷酰胺、阿霉素、米托蒽醌和顺铂。随着更结构化评估方法的引入，包括仔细评估生活质量指标和连续测量血清前列腺特异性抗原（PSA），细胞毒性药物的作用正在重新评估。鉴于前列腺癌的细胞周期特征，有丝分裂联合抑制剂似乎有新的作用，包括雌莫司汀与长春花生物碱、依托泊苷或紫杉醇联合使用。
